Pharma's slow take-up of digital technology is hurting R&D, report reveals

27 May 2016

Slow take-up of new digital technologies is hindering the progress of pharma in research and development (R&D) and improving patient outcomes, according to Accenture.

The consulting firm has produced a report entitled Industry at a Crossroads: The Rise of Digital in the Outcome-Driven R&D Organization. This report notes the fundamental ongoing shift in pharma from a product-orientated outlook to a patient and health system outcome focus.

Accenture reports that digital solutions are injecting process improvement and additional value across the enterprise, from R&D to commercial to medical affairs. The company therefore surveyed 76 of the top global R&D executives, based in the USA and Europe, to see how these new innovations are impacting their organizations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK